Skip to main navigation Skip to search Skip to main content

Nye behandlingsmuligheder ved primær immun trombocytopeni

Translated title of the contribution: [New treatment options for primary immune thrombocytopenia]
  • Sif Gudbrandsdottir
  • , Henrik Frederiksen
  • , Henrik Sverre Birgens
  • , Claus Henrik Nielsen
  • , Ove Juul Nielsen
  • , Jesper Stentoft
  • , Hans Carl Hasselbalch

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

Primary immune thrombocytopenia (ITP)--formerly known as idiopathic thrombocytopenic purpura--is an autoimmune disorder characterized by immune mediated thrombocytopenia. The aetiology of ITP remains unknown, but studies have shown that multiple immunological mechanisms are involved in the pathogenesis of ITP. This article aims to provide an overview of current treatment options, with particular emphasis on new biological therapies: rituximab, a monoclonal anti-CD20 antibody, and the thrombopoietin receptor agonists romiplostim and eltrombopag.
Translated title of the contribution[New treatment options for primary immune thrombocytopenia]
Original languageDanish
JournalUgeskrift for Læger
Volume173
Issue number4
Pages (from-to)271-4
Number of pages4
ISSN0041-5782
Publication statusPublished - 2011

Fingerprint

Dive into the research topics of '[New treatment options for primary immune thrombocytopenia]'. Together they form a unique fingerprint.

Cite this